TY - JOUR
T1 - Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer
T2 - a multicenter retrospective study
AU - Uda, Sayaka
AU - Yamada, Tadaaki
AU - Yoshimura, Akihiro
AU - Goto, Yasuhiro
AU - Yoshimine, Kohei
AU - Nakamura, Yoichi
AU - Shiotsu, Shinsuke
AU - Yokoi, Takashi
AU - Tamiya, Nobuyo
AU - Kimura, Hideharu
AU - Chihara, Yusuke
AU - Umeda, Yukihiro
AU - Izumi, Miiru
AU - Takeda, Takayuki
AU - Yamada, Takahiro
AU - Hibino, Makoto
AU - Hiranuma, Osamu
AU - Ito, Kazuhiro
AU - Okada, Asuka
AU - Osugi, Shuji
AU - Takemura, Yoshizumi
AU - Ishii, Hiroshi
AU - Chibana, Kenji
AU - Hasegawa, Isao
AU - Morimoto, Yoshie
AU - Iwasaku, Masahiro
AU - Tokuda, Shinsaku
AU - Takayama, Koichi
N1 - Publisher Copyright:
© Translational Lung Cancer Research. All rights reserved.
PY - 2022/9
Y1 - 2022/9
N2 - Background: Topoisomerase is an essential enzyme for deoxyribonucleic acid replication, and its inhibitors suppress tumor progression. Amrubicin, a topoisomerase II inhibitor, is mainly used in the second-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). However, the impact of different types of topoisomerase inhibitors for first-line chemotherapy on the efficacy of amrubicin remains unclear. In the present study, we aimed to evaluate the efficacy of second-line amrubicin in patients with relapsed SCLC who were previously treated with platinum-based chemotherapy, including topoisomerase I and II inhibitors. Methods: This study retrospectively analyzed patients with ES-SCLC who experienced recurrence and were treated with amrubicin at 22 institutions in Japan between April 2015 and November 2020. The progression-free survival of amrubicin monotherapy was investigated using the Kaplan-Meier method. Results: A total of 320 patients were enrolled in this study, with 59 (18%) receiving platinum plus topoisomerase I inhibitor irinotecan and 261 (82%) receiving platinum plus topoisomerase II inhibitor etoposide as first-line treatment. The progression-free survival of amrubicin was significantly longer in the irinotecan group than in the etoposide group (3.2 vs. 2.5 months; P=0.034). Conclusions: These results showed that different types of topoisomerase inhibitors could affect the efficacy of amrubicin monotherapy in the second-line treatment of patients with relapsed ES-SCLC.
AB - Background: Topoisomerase is an essential enzyme for deoxyribonucleic acid replication, and its inhibitors suppress tumor progression. Amrubicin, a topoisomerase II inhibitor, is mainly used in the second-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). However, the impact of different types of topoisomerase inhibitors for first-line chemotherapy on the efficacy of amrubicin remains unclear. In the present study, we aimed to evaluate the efficacy of second-line amrubicin in patients with relapsed SCLC who were previously treated with platinum-based chemotherapy, including topoisomerase I and II inhibitors. Methods: This study retrospectively analyzed patients with ES-SCLC who experienced recurrence and were treated with amrubicin at 22 institutions in Japan between April 2015 and November 2020. The progression-free survival of amrubicin monotherapy was investigated using the Kaplan-Meier method. Results: A total of 320 patients were enrolled in this study, with 59 (18%) receiving platinum plus topoisomerase I inhibitor irinotecan and 261 (82%) receiving platinum plus topoisomerase II inhibitor etoposide as first-line treatment. The progression-free survival of amrubicin was significantly longer in the irinotecan group than in the etoposide group (3.2 vs. 2.5 months; P=0.034). Conclusions: These results showed that different types of topoisomerase inhibitors could affect the efficacy of amrubicin monotherapy in the second-line treatment of patients with relapsed ES-SCLC.
UR - http://www.scopus.com/inward/record.url?scp=85139875425&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139875425&partnerID=8YFLogxK
U2 - 10.21037/tlcr-22-160
DO - 10.21037/tlcr-22-160
M3 - Article
AN - SCOPUS:85139875425
SN - 2226-4477
VL - 11
SP - 1847
EP - 1857
JO - Translational Lung Cancer Research
JF - Translational Lung Cancer Research
IS - 9
ER -